

# UP TO 70% OF CHRONIC Q FEVER CASES MAY PRESENT WITH ENDOCARDITIS<sup>1-3</sup>



WEBINAR

## FACTS, FEVER & ENDOCARDITIS:

Q fever update for  
primary care

**Join Dr Penny Hutchinson and  
Dr Robert Horvath** as they explore  
the changing epidemiology of Q fever  
in regions such as the Darling Downs  
(QLD) and review how chronic Q fever  
can be diagnosed and managed.

**When: Wednesday 7th September 2022**

7pm start (AEST)

To register and reserve your spot click the  
link below or simply scan the QR code

REGISTER NOW >



[www.seqirus.com.au](http://www.seqirus.com.au)

  
A CSL COMPANY



## Why attend?

### The epidemiology of the zoonotic infection *Coxiella burnetii* that causes Q fever is changing<sup>3</sup>.

Primary care plays an active role in identifying acute (e.g. fever) and chronic manifestations (e.g. endocarditis) of this nationally notifiable disease<sup>2</sup>. Traditionally, Q fever risk has predominantly been attributed to occupational exposure through working alongside infected animals, mainly sheep, cattle and goats<sup>4</sup>.

**Attend this event to learn more about the groups most at risk within Australia and why it's important to diagnose early to help minimise long-term complications in your patients.**

## Event proceedings

Time	Agenda:
7:00pm	 <b>Changing epidemiology and current landscapes of Q fever in Australia.</b> <b>Dr Penny Hutchinson</b> , Public Health Physician and Epidemiologist, QLD Health
7:45pm	 <b>Clinical manifestations of chronic Q fever, including endocarditis.</b> <b>Dr Robert Horvath</b> , Infectious Diseases Physician and Clinical Microbiologist, The Prince Charles Hospital
8:30pm	Meeting close



WEBINAR

To register and reserve your spot click the link below or simply scan the QR code

REGISTER NOW >



**References:** **1.** Parker, N.R., J.H. Barralet, and A.M. Bell, Q fever. *Lancet*, 2006. 367(9511): p. 679-88. **2.** Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook, Australian Government Department of Health. 2021 [cited 2022 July 22]; Available from: <https://immunisationhandbook.health.gov.au/vaccine-preventable-diseases/q-fever>. **3.** Karki S, et al. Risk factors and the burden of acute Q fever in older adults in New South Wales: a prospective study. *Med J Aust.* 2015; 203(11):438 **4.** Sloan-Gardner T.S., et al. Trends and risk factors for human Q fever in Australia, 1991–2014. *Epidemiol Infect* 2017;145(4):787–95.

By registering for this event, you agree that you are a healthcare professional registered to practice in Australia and consent to your data being collected in accordance with the Seqirus Privacy Policy ([www.seqirus.com.au/privacy-statement](http://www.seqirus.com.au/privacy-statement)) and agree to receiving communications from Seqirus in relation to this event. As Seqirus abides by the Medicines Australia Code of Conduct, only invitees may attend this event. Any costs (e.g. travel or meals) incurred by a partner/spouse, guest or family member travelling with a healthcare professional attending this event cannot be paid for or subsidised by Seqirus. Attendees are responsible for obtaining approval to receive and/or disclose hospitality as required by their employer or professional association.

**Privacy Notice:** The information requested on this form will be used by Seqirus (Australia) Pty Ltd. and its related bodies corporate ("Seqirus") in connection with the purposes set out in this form. If this information is not provided it may not be possible to perform the function or service in relation to which we requested the information. We may disclose personal information to third parties including related companies, regulatory authorities and contractors engaged to provide services to Seqirus. Some of these entities may be located outside of Australia. The countries in which recipients may be located include (but are not limited to) the United States, Switzerland and countries within the European Union. To the extent that you may be entitled to do so under the Privacy Act and any other applicable laws, you may request access to, or correction of, your personal information held by Seqirus by contacting Seqirus' Privacy Officer on email: [privacy@cslbehring.com](mailto:privacy@cslbehring.com), phone: (03) 9389 2000, or by writing to Seqirus, Tower One, Level 12, Collins Square, 727 Collins Street, Melbourne Victoria 3008, Australia. Further information regarding Seqirus' handling of personal information, including how you can seek access to or correction of personal information held about you by Seqirus and how you can make a complaint about our handling of personal information, is set out in our Privacy Policy available at [www.seqirus.com.au/privacy-statement](http://www.seqirus.com.au/privacy-statement).



This initiative is funded by the Australian Government Department of Health.

Seqirus Pty Ltd. ABN 26 120 735 035. Tower 1, Level 12, Collins Square, 727 Collins Street, Docklands VIC 3008. Seqirus™ is a trademark of Seqirus UK Limited or its affiliates. Seqirus Medical Information: 1800 642 865. ANZ-QVAX-22-0011. Date of preparation: July 2022.

